These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 6599676

  • 21. Mesenteric vascular responses to vasopressin during development of DOCA-salt hypertension in male and female rats.
    Stallone JN.
    Am J Physiol; 1995 Jan; 268(1 Pt 2):R40-9. PubMed ID: 7840337
    [Abstract] [Full Text] [Related]

  • 22. Effect of exercise training on liver antioxidant status of deoxycorticosterone acetate salt induced hypertensive rats.
    Elhaïmeur F, Courderot-Masuyer C, Nicod L, Bobillier-Chaumont S, Robin S, Richert L, Berthelot A.
    Can J Physiol Pharmacol; 2003 May; 81(5):469-75. PubMed ID: 12774853
    [Abstract] [Full Text] [Related]

  • 23. Endothelium, vasopressin receptors, and resistance to DOCA-salt hypertension.
    Bockman CS, Jeffries WB, Pettinger WA, Abel PW.
    Am J Physiol; 1993 Jul; 265(1 Pt 2):H15-21. PubMed ID: 8342627
    [Abstract] [Full Text] [Related]

  • 24. Age-dependent DOCA-salt hypertension in Brattleboro rats: the role of vasopressin.
    Zicha J, Kunes J, Jelínek J.
    Physiol Bohemoslov; 1987 Jul; 36(1):33-42. PubMed ID: 2954169
    [Abstract] [Full Text] [Related]

  • 25. Central vasopressin receptors are upregulated by deoxycorticosterone acetate.
    Swords BH, Wyss JM, Berecek KH.
    Brain Res; 1991 Sep 13; 559(1):10-6. PubMed ID: 1838296
    [Abstract] [Full Text] [Related]

  • 26. Regulation of vasopressin receptors in deoxycorticosterone acetate-salt hypertension.
    Trinder D, Phillips PA, Risvanis J, Stephenson JM, Johnston CI.
    Hypertension; 1992 Oct 13; 20(4):569-74. PubMed ID: 1398892
    [Abstract] [Full Text] [Related]

  • 27. Renal AT1 receptor: computerized quantification in spontaneously hypertensive rats and DOCA-salt rats.
    Asano N, Ogura T, Mimura Y, Otsuka F, Kishida M, Hashimoto M, Yamauchi T, Makino H.
    Res Commun Mol Pathol Pharmacol; 1998 May 13; 100(2):171-80. PubMed ID: 9667071
    [Abstract] [Full Text] [Related]

  • 28. Evaluation of the pharmacologic properties of a vasopressin antagonist in Brattleboro rats.
    Mah SC, Hofbauer KG.
    J Pharmacol Exp Ther; 1988 Jun 13; 245(3):1028-32. PubMed ID: 2968448
    [Abstract] [Full Text] [Related]

  • 29. Vasopressin induces vascular superoxide via endothelin-1 in mineralocorticoid hypertension.
    Li L, Galligan JJ, Fink GD, Chen AF.
    Hypertension; 2003 Mar 13; 41(3 Pt 2):663-8. PubMed ID: 12623976
    [Abstract] [Full Text] [Related]

  • 30. Effect of vasopressin V1- and V2-receptor stimulation on blood pressure in DOCA-salt hypertensive rats.
    Mimura Y, Ogura T, Yamauchi T, Otsuka F, Oishi T, Harada K, Hashimoto M, Ota Z.
    Acta Med Okayama; 1995 Aug 13; 49(4):187-94. PubMed ID: 7502678
    [Abstract] [Full Text] [Related]

  • 31. Role of AVP in malignant DOC-salt hypertension: studies using vascular and antidiuretic antagonists.
    Filep J, Frölich JC, Földes-Filep E.
    Am J Physiol; 1987 Nov 13; 253(5 Pt 2):F952-8. PubMed ID: 3688242
    [Abstract] [Full Text] [Related]

  • 32. Renal function contributes to antihypertensive effect of vasopressin in DOCA-salt but not spontaneous hypertension.
    Wang H, McNeill JR.
    Am J Physiol; 1994 Nov 13; 267(5 Pt 2):H1842-50. PubMed ID: 7977814
    [Abstract] [Full Text] [Related]

  • 33. Lack of increase in concentrations of cerebrospinal fluid sodium in rats with various stages of DOCA-salt hypertension.
    Takata Y, Yamashita Y, Takishita S, Fujishima M.
    Life Sci; 1988 Nov 13; 42(12):1223-9. PubMed ID: 3347147
    [Abstract] [Full Text] [Related]

  • 34. Endothelin antagonist reduces hemodynamic responses to vasopressin in DOCA-salt hypertension.
    Yu M, Gopalakrishnan V, Wilson TW, McNeill JR.
    Am J Physiol Heart Circ Physiol; 2001 Dec 13; 281(6):H2511-7. PubMed ID: 11709418
    [Abstract] [Full Text] [Related]

  • 35. Arginine vasopressin induced motor disturbances in the medial amygdala: evidence for the involvement of a V1-type of AVP receptor.
    Willcox BJ, Poulin P, Pittman QJ, Veale WL.
    Proc West Pharmacol Soc; 1991 Dec 13; 34():291-5. PubMed ID: 1788301
    [No Abstract] [Full Text] [Related]

  • 36. Deoxycorticosterone acetate-salt rats: hypertension and sympathoexcitation driven by increased NaCl levels.
    O'Donaughy TL, Brooks VL.
    Hypertension; 2006 Apr 13; 47(4):680-5. PubMed ID: 16520400
    [Abstract] [Full Text] [Related]

  • 37. Synthesis and some pharmacological properties of new V1/V2 antagonists of arginine-vasopressin with structural changes at their N-terminals.
    Lammek B, Konieczna E, Wierzba T, Wang YX, Gavras H.
    Pol J Pharmacol Pharm; 1992 Apr 13; 44(2):179-86. PubMed ID: 1409118
    [Abstract] [Full Text] [Related]

  • 38. Changes in vascular vasopressin receptors and responsiveness in DOCA/NaCl-treated rats.
    Smith CD, Pearlmutter F, Szkrybalo M, Katovich MJ.
    Clin Exp Hypertens A; 1988 Apr 13; 10(4):629-47. PubMed ID: 2968870
    [Abstract] [Full Text] [Related]

  • 39. Histometric assessment of renal arterioles during DOCA and post-DOCA hypertension and hydralazine treatment in rats.
    Vial JH, Boyd GW.
    J Hypertens; 1989 Mar 13; 7(3):203-9. PubMed ID: 2708816
    [Abstract] [Full Text] [Related]

  • 40. Biologic response to chronic blockade of vasopressin receptors in Sprague-Dawley rats.
    Mah SC, Opperman JR, Baum HP, Hofbauer KG.
    J Pharmacol Exp Ther; 1988 Jun 13; 245(3):1021-7. PubMed ID: 2968447
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.